For example, novel therapeutic options are being tested in AML using inhibitors of Fms-Like Tyrosine kinase-3 (FLT3), isocitrate dehydrogenase (IDH), B-cell lymphoma 2 (BCL-2), FOXO3A (a forkhead transcription factor) inhibitor, or with stabilizers of p53 (3–5, 16–20). This evidence concerns the gene IDH2 and acute myeloid leukemia.